Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Maintenance After Induction Chemotherapy in Elderly Patients With Advanced Non-small Cell Lung Cancer (MODEL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01850303
Recruitment Status : Completed
First Posted : May 9, 2013
Last Update Posted : February 10, 2021
Information provided by (Responsible Party):
Intergroupe Francophone de Cancerologie Thoracique

Brief Summary:

For elderly patient, the treatment of Non Small Cell Lung Cancer was based on monotherapy but IFCT-0501 trial begun in 2006, demonstrated that a bitherapy (carboplatin and paclitaxel) is better than monotherapy in term of overall survival and progression free survival. The current recommendations are now to administer a carboplatin based bitherapy (4 or 6 cycles). After the treatment is stopped until progression and initiation of a second line treatment. The risk of this strategy is to be confronted to a rapid disease progression during the free interval. Indeed, about 1/3 of the patients whose disease was controlled after the chemotherapy do not receive 2nd line. The concept of maintenance is based on a continuous therapeutic pressure in order to preserve the therapeutic profit obtained by the treatment of 1st line (induction chemotherapy).

There is two types of maintenance :

  • continuous maintenance therapy which consists in continuing the treatment initially associated with platinum until disease progression.
  • switch maintenance which consists in introducing a new treatment after the end of induction chemotherapy The two types are validated by several trials. The marketing authorization of pemetrexed was enlarged to maintenance for non squamous carcinoma.

Gemcitabine has a good tolerance profile which make possible the use in a maintenance strategy. Several trials evaluated maintenance with this product and some show benefits in term of progression free survival.

The objective of this trial is to evaluate the switch maintenance in elderly patient with a controlled disease after 4 cycles of chemotherapy carboplatin-paclitaxel.

Condition or disease Intervention/treatment Phase
Non Small Cell Lung Cancer (Squamous or Non Squamous) Drug: Pemetrexed Drug: Gemcitabine Drug: Induction chemotherapy Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 632 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase III Study Comparing Maintenance With Pemetrexed or Gemcitabine to a Surveillance in Elderly Patients (70 Years Old and More) With a Advanced Non Small Cell Lung Cancer Controlled by Induction Chemotherapy.
Actual Study Start Date : May 16, 2013
Actual Primary Completion Date : August 20, 2018
Actual Study Completion Date : January 31, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer

Arm Intervention/treatment
Surveillance Drug: Induction chemotherapy
4 cycles of carboplatin-paclitaxel

Experimental: Maintenance
Pemetrexed for non squamous NSCLC Gemcitabine for squamous NSCLC
Drug: Pemetrexed
Drug: Gemcitabine
Drug: Induction chemotherapy
4 cycles of carboplatin-paclitaxel

Primary Outcome Measures :
  1. Overall survival [ Time Frame: Up to 15 months ]

Secondary Outcome Measures :
  1. Feasibility of treatment (number of cycles of maintenance) [ Time Frame: 84 days on average ]
    Number of cycles of maintenance (median)

  2. Progression free survival [ Time Frame: up to 7 months ]
  3. response and stabilisation duration [ Time Frame: up to 7 months ]
  4. Number of patient with at least one adverse event [ Time Frame: up to 7 months ]
  5. Treatment duration [ Time Frame: Up to 7 months ]
  6. 2nd line response rate [ Time Frame: Up to 4 months ]
  7. Number of adverse events [ Time Frame: Up to 7 months ]
  8. 2nd line overall survival [ Time Frame: Up to 7 months ]
  9. 2nd line progression free survival [ Time Frame: Up to 4 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   70 Years to 89 Years   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically documented Non Small Cell Lung Cancer non resectable or non irradiable stage III or stage IV
  • EGFR wild type or non feasible EGFR
  • 90 >Age ≥ 70
  • ECOG Performance status : 0, 1 or 2
  • Mini-Mental Test Status (MMS) > 23

Exclusion Criteria:

  • Mixed non-small cell and small cell tumors
  • Patients with EGFR mutated tumor
  • Patient with EML4-ALK translocation
  • Evolutive or symptomatic metastasis of central nervous system
  • Superior vena cava syndrome
  • Calcemia > 2,70 mmol/L

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01850303

Show Show 78 study locations
Sponsors and Collaborators
Intergroupe Francophone de Cancerologie Thoracique
Additional Information:
Layout table for additonal information
Responsible Party: Intergroupe Francophone de Cancerologie Thoracique Identifier: NCT01850303    
Other Study ID Numbers: IFCT-1201
First Posted: May 9, 2013    Key Record Dates
Last Update Posted: February 10, 2021
Last Verified: February 2021
Keywords provided by Intergroupe Francophone de Cancerologie Thoracique:
lung cancer
Elderly patients (between 70 and 89 years)
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Folic Acid Antagonists
Nucleic Acid Synthesis Inhibitors